Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Visiongain Reports | Outsourcing for contract manufacturing services 2008-2023

Outsourcing for contract manufacturing services 2008-2023

The revenue for world contract manufacturing business in 2007 was approximately $30bn, with a growth rate of 6% from 2006. The technical expertise and cost savings offered by contract manufacturing organisations (CMOs) make them increasingly essential to you and your organisation. Greater emphasis has been put on European CMOs to leverage low-cost contract manufacturing markets, such as those existing in India and China, to enhance cost efficiency. Many CMOs in Europe have turned to biotech services as a means of avoiding competition with lower-cost API companies based in developing countries. In common with European service providers, North American CMOs are adopting a dynamic approach. Also, they are providing other services, such as packaging, logistics and marketing support. Are you taking advantage of the opportunities available? This unique report will guide you and inform you on how to benefit from the options - you should take the opportunity today.

Recent years have seen the emergence of moderate level competition from Indian and Chinese CMOs. This new visiongain report - Contract Pharma 2008-2023 - evaluates the prospects for outsourcing manufacturing and other operations from pharmaceutical companies, especially off-shoring to developing nations such as China and India. Furthermore, this report analyses the increasing trend for Japan to outsource services abroad.

In particular, the following factors have been highlighted in this report:

• Synchronization of regulations

• Mutual recognition of GMP documentation

• Improved information exchange.

Why you should buy this report:

In Contract Pharma 2008-2023 you will receive the following essential information for understanding the contract pharma market:

- The value of the contract pharma business market and its principal market segments from 2008 to 2023, with detailed forecasts and growth analyses

- Market drivers and restraints, including a comprehensive SWOT analysis

- Comprehensive views of key opinion leaders on contract pharma, including leading companies, with full interview transcripts from our in-depth survey worldwide

- The companies involved in contract pharma business and their business strategy

- The present state of contract pharma business and future trends there

- What contract pharma opportunities exist for market entrants, both established companies and newcomers

- The main concerns for outsourcing clinical trials to CROs

- Changes in contract pharma regulations

- CMOs are increasingly undertaking analytical testing and other value-added services alongside traditional contract manufacturing of APIs. In some major CMOs, these value-added services have taken up significant proportion of their revenue generation. This rate will increase further in the coming decade. The establishment of large, global companies offering a full range of contract services has led to a change in the image of CROs and CMOs. There has been a shift in the business model of CMOs to integrate themselves more fully into the supply chain of pharmaceutical and biopharmaceutical companies by offering a wider range of services.

The report is intended for the following professionals, amongst others:

- Directors, business development managers and researchers of pharmaceutical and biopharmaceutical companies worldwide

- Directors, business development managers and researchers in the healthcare industry

- Policy makers, researchers, analysts and academic researchers

- PRICING -

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD $5,995.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only USD $9,995.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD $13,995.00

Publication date: 15/08/2008

Number of Pages: 127
Table of Contents

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions